Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors
Jian Li(Shanghai Medical Information Center), Lin Shen(Peking University), Yunong Gao(Ministry of Education), Ye Xu(Fudan University Shanghai Cancer Center), Aimin Zang, Jin Wang(Baylor College of Medicine), Chunmei Shi(Huazhong Agricultural University), Jing Wang(Qingdao University), Yanhong Deng(Sun Yat-sen University), Jianming Xu(Chinese PLA General Hospital), Tianshu Liu(Sun Yat-sen University), Sheng Hu(Hubei Cancer Hospital), Yi Huang(Shenzhen Institutes of Advanced Technology), Yue-Yin Pan(Anhui Provincial Hospital), Haiping Jiang(Zhejiang Chinese Medical University), Xiaoping Qian(Second Affiliated Hospital of Nanjing Medical University), Han Hu(BeiGene (China)), Quanli Gao(Henan Cancer Hospital), Yanqiao Zhang(Harbin Medical University), Mengyue Shi(BeiGene (China)), Ying Cheng(Wenzhou Medical University), Dong Wang(University of Minnesota), Ying Yuan(The University of Texas MD Anderson Cancer Center), Ke Wang(Pennsylvania State University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 18
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
|Signal Transduction and Targeted Therapy|2020|1.2k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657